Desimone v. Industrial Bio-Test Laboratories, Inc.

83 F.R.D. 615, 1979 U.S. Dist. LEXIS 9400
CourtDistrict Court, S.D. New York
DecidedOctober 2, 1979
DocketNos. 76 Civ. 3506 (LFM), 77 Civ. 5823 (LFM)
StatusPublished
Cited by29 cases

This text of 83 F.R.D. 615 (Desimone v. Industrial Bio-Test Laboratories, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Desimone v. Industrial Bio-Test Laboratories, Inc., 83 F.R.D. 615, 1979 U.S. Dist. LEXIS 9400 (S.D.N.Y. 1979).

Opinion

OPINION

MacMAHON, District Judge.

The parties in this consolidated securities fraud class action apply for approval of a proposed settlement under Rule 23(e), Fed. R.Civ.P. Plaintiffs’ counsel also apply for allowances of attorneys’ fees and expenses.

Plaintiffs, purchasers of Syntex Corporation stock and options, allege that defendants Syntex Corporation, one of its subsidiaries, certain of its officers and directors (the “Syntex defendants”), and Industrial Bio-Test Laboratories, Inc. (“IBT”) committed common law fraud and violated Section 10(b) of the Securities Exchange Act, 15 U.S.C. § 78j(b), and Rule 10b-5 thereunder, 17 C.F.R. § 240.10b-5. The nub of the allegations is that in obtaining approval from the United States Food and Drug Administration (“FDA”) to market Syntex’s drug, Naprosyn, the Syntex defendants submitted to the FDA a report, prepared by IBT, that contained false and misleading statements regarding Naprosyn’s toxicity to humans. When the FDA later learned of the report’s unreliability, it commenced proceedings to withdraw Naprosyn’s approval, with the result that Syntex’s stock and options prices dropped.

Plaintiff Desimone, a stock purchaser, commenced this action on August 6, 1976. Later, in September 1976, plaintiff Maddal-oni, also a stock purchaser, brought an action in the United States District Court for the Northern District of California. The California action was transferred here and consolidated with the Desimone action by our order of June 6, 1977. On the same date, we ordered conditional certification of this consolidated action (the “Desimone action”) as a class action on behalf of all persons who sustained damage as a result of their purchase of Syntex common stock during the period from October 13, 1975 through August 6, 1976 (the “stock class”).

Plaintiff Lloyd, purchaser of an option to purchase Syntex stock, brought his action here on December 2, 1977. We ordered consolidation with the stock class action and’ designated as co-lead counsel the two law [618]*618firms representing the stock class. We twice denied certification of the option class.

After extensive discovery and with the trial date near, counsel, in February 1979, negotiated a stipulation of settlement of all claims for approximately $2,900,000. We then entered an order for purposes of such settlement only allowing the Lloyd action to proceed as a class action on behalf of all persons who sustained damage as a result of their purchase of options to purchase Syntex common stock during the period from October 13, 1975 through August 6, 1976 (the “option class”).

Pursuant to our order of May 8, 1979, notice of the proposed settlement was mailed to the stock and option class members and published in the national edition of the Wall Street Journal. The notice outlined the terms of the settlement and the fees and expenses sought by plaintiffs’ counsel, gave notice of a hearing on those matters to be held July 30, 1979, and informed class members of their rights to object to the arrangement and to opt out of the settlement. On July 30, 1979, we held the noticed hearing, and there were no objections to the settlement and requested fees and expenses.

We now consider the propriety of the settlement and the fee applications.

The Settlement

The stipulation of settlement provided that defendants were to contribute $2,750,-000 to a settlement fund, and they did so in February 1979. Should distribution be approved, the total fund will contain that contribution plus interest, which as of July 30, 1979 amounted to $125,000. Proponents estimate that by the time of payout the fund will contain about $3,000,000. Lawyers’ fees and litigation expenses are to be paid out of this fund, and plaintiffs’ counsel have stipulated that total fees are not to exceed $900,000. In addition, the Syntex defendants have agreed to reimburse up to $50,000 of the expenses incurred by plaintiffs’ counsel in the notification and administration of the settlement. Such expenses to date total $33,526.33.

The court will approve a proposed settlement of a class action if the proposal is fair, reasonable and adequate. This determination requires three levels of analysis. First, the proponents have the burden of proving that (1) the settlement is not collusive but was reached after arm’s length negotiation; (2) the proponents are counsel experienced in similar cases; (3) there has been sufficient discovery to enable counsel to act intelligently and (4) the number of objectants or their relative interest is small. If the proponents establish these propositions, the burden of attacking the settlement then shifts to the objectants, if ány. Finally, the court must approve the settlement only after finding it to be reasonable in light of the plaintiffs’ ultimate probability of success in the lawsuit.1

We find that the proponents have established the four propositions stated above. The negotiations between plaintiffs’ lead counsel and defendants’ counsel took place at arm’s length.2 Counsel for the option class were apparently absent from the bulk of the negotiations. Nevertheless, after the lead counsel negotiated a settlement for the option purchasers reimbursing them for 10% of their alleged loss, the option counsel succeeded in increasing this amount to 15%.3 This fact suggests meaningful participation at arm’s length. There is no suggestion of collusion anywhere in the evidence.

All proponents are able and respected counsel with substantial experience in stockholder litigation, federal securities [619]*619fraud litigation and class actions.4 Proponents have shown that the discovery has been extensive and exhaustive. Defendants produced hundred of thousands of pages of documents; plaintiffs conducted more than 45 days of depositions of 41 witnesses; and the parties entered into numerous stipulations of fact so as to focus and narrow the range of contested issues.5

The number of objectants and their relative interests appear to be zero. As of July 30, 1979, no class member had objected, and over 4,000 members had submitted claims to share in the settlement fund.6 Though some persons have requested exclusion from the option class, the court is unaware of any objectants.

The proponents have thus clearly borne their initial burden. Since there is no objectant, the court must now engage in determining whether the settlement is reasonable in light of plaintiffs’ probabilities of success on the merits. The purpose of this investigation is to assure that the interests of class members absent from the litigation and settlement negotiations remain protected.7 In protecting these interests, we are not to substitute our business judgment for that of the negotiators who bargained at arm’s length, but only to insure that the arrangement is not so unfair as to require disapproval.8

In determining reasonableness, the courts in this circuit have not applied any single, inflexible test.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Carpi v. McDonnell Douglas Capital Income Fund-I
838 F. Supp. 729 (S.D. New York, 1998)
Goodwin v. Boesky
888 F. Supp. 551 (S.D. New York, 1995)
In Re Boesky Securities Litigation
888 F. Supp. 551 (S.D. New York, 1995)
Trief v. Dun & Bradstreet Corp.
840 F. Supp. 277 (S.D. New York, 1993)
In RE McDONNELL DOUGLAS EQUIP. LEASING SEC. LIT.
838 F. Supp. 729 (S.D. New York, 1993)
Browning v. Peyton
123 F.R.D. 75 (S.D. New York, 1988)
Schwartz v. Novo Industri A/S
119 F.R.D. 359 (S.D. New York, 1988)
Campaign for a Progressive Bronx v. Black
631 F. Supp. 975 (S.D. New York, 1986)
Spell v. McDaniel
616 F. Supp. 1069 (E.D. North Carolina, 1985)
In Re "Agent Orange" Product Liability Litigation
611 F. Supp. 1296 (E.D. New York, 1985)
In Re Baldwin-United Corp.(single Premium Defer.)
607 F. Supp. 1312 (S.D. New York, 1985)
In Re Jensen-Farley Pictures, Inc.
47 B.R. 557 (D. Utah, 1985)
Zacharias v. Shell Oil Co.
627 F. Supp. 31 (E.D. New York, 1984)
Capozzi v. City of Albany
565 F. Supp. 771 (N.D. New York, 1983)
Feuerstein v. Burns
569 F. Supp. 268 (S.D. California, 1983)
New York State Ass'n for Retarded Children, Inc. v. Carey
544 F. Supp. 330 (E.D. New York, 1982)
Ramos v. Lamm
539 F. Supp. 730 (D. Colorado, 1982)

Cite This Page — Counsel Stack

Bluebook (online)
83 F.R.D. 615, 1979 U.S. Dist. LEXIS 9400, Counsel Stack Legal Research, https://law.counselstack.com/opinion/desimone-v-industrial-bio-test-laboratories-inc-nysd-1979.